LI-RADS category 5 (LR-5) assessment had an 11 percent higher AUC for detecting hepatocellular carcinoma (HCC) in patients with non-cirrhotic chronic hepatitis C (CHC) in comparison to those with cirrhotic CHC.
LI-RADS category 5 (LR-5) assessment had an 11 percent higher AUC for detecting hepatocellular carcinoma (HCC) in patients with non-cirrhotic chronic hepatitis C (CHC) in comparison to those with cirrhotic CHC.